Clinical Trial Update: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating elacestrant alone versus elacestrant plus a CDK4/6 inhibitor in ER-positive, HER2-negative advanced or metastatic breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor (unspecified)
• Elacestrant (elacestrant)

Snippet

Sponsor: Northwestern University | Conditions: Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer | Phase 2 | Status: RECRUITING